Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.

Gupta S, Argani P, Jungbluth AA, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Sanchez A, Hakimi AA, Mcfarlane T, Salazar PA, Williamson SR, Skala SL, Mehra R, Hes O, Antonescu CR, Ladanyi M, Arcila ME, Reuter VE.

Am J Surg Pathol. 2019 Nov;43(11):1445-1461. doi: 10.1097/PAS.0000000000001307.

PMID:
31600176
2.

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.

Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.

Mod Pathol. 2019 Sep 19. doi: 10.1038/s41379-019-0364-z. [Epub ahead of print]

PMID:
31537897
3.

Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.

Hodgson A, Jungbluth AA, Katabi N, Xu B, Downes MR.

Virchows Arch. 2019 Sep 2. doi: 10.1007/s00428-019-02661-2. [Epub ahead of print]

PMID:
31485721
4.

Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool in diagnosing secretory carcinoma of salivary gland and detecting ETV6-NTRK3 fusion.

Xu B, Haroon Al Rasheed MR, Antonescu CR, Alex D, Frosina D, Ghossein R, Jungbluth AA, Katabi N.

Histopathology. 2019 Aug 25. doi: 10.1111/his.13981. [Epub ahead of print]

PMID:
31448442
5.

CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.

Buonocore DJ, Konno F, Jungbluth AA, Frosina D, Fayad M, Edelweiss M, Lin O, Rekhtman N.

Cancer Cytopathol. 2019 Oct;127(10):643-649. doi: 10.1002/cncy.22170. Epub 2019 Aug 9.

PMID:
31398281
6.

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0324-7. [Epub ahead of print]

PMID:
31375766
7.

Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.

Downes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B.

Histopathology. 2019 Jun 27. doi: 10.1111/his.13946. [Epub ahead of print]

PMID:
31243779
8.

The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.

Xu B, Jungbluth AA, Frosina D, Alzumaili B, Aleynick N, Slodkowska E, Higgins K, Ho A, Morris L, Ghossein R, Katabi N.

Histopathology. 2019 Jun 25. doi: 10.1111/his.13944. [Epub ahead of print]

PMID:
31237963
9.

DNA methylation-based classification of sinonasal undifferentiated carcinoma.

Dogan S, Vasudevaraja V, Xu B, Serrano J, Ptashkin RN, Jung HJ, Chiang S, Jungbluth AA, Cohen MA, Ganly I, Berger MF, Momeni Boroujeni A, Ghossein RA, Ladanyi M, Chute DJ, Snuderl M.

Mod Pathol. 2019 Oct;32(10):1447-1459. doi: 10.1038/s41379-019-0285-x. Epub 2019 Jun 11.

PMID:
31186531
10.

Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, Jungbluth AA, Frosina D, Slotkin E, Shukla N, Meyers P, Healey JH, Hameed M, Ladanyi M.

Clin Cancer Res. 2019 Jun 7. doi: 10.1158/1078-0432.CCR-18-4032. [Epub ahead of print]

PMID:
31175097
11.

JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.

Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Blum KA, Lohse CM, Hakimi AA, Thompson RH, Leibovich BC, Berger MF, Arcila ME, Ross DS, Ladanyi M, Antonescu CR, Reuter VE.

Mod Pathol. 2019 Sep;32(9):1344-1358. doi: 10.1038/s41379-019-0269-x. Epub 2019 Apr 17.

PMID:
30996253
12.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.

PMID:
30877085
13.

Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.

Hechtman JF, Klimstra DS, Nanjangud G, Frosina D, Shia J, Jungbluth AA.

Pancreas. 2019 Mar;48(3):396-399. doi: 10.1097/MPA.0000000000001256.

PMID:
30747827
14.

Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.

Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.

Cancer Immunol Res. 2019 Apr;7(4):658-669. doi: 10.1158/2326-6066.CIR-18-0198. Epub 2019 Feb 11.

PMID:
30745365
15.

Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas.

Pareja F, Geyer FC, Brown DN, Sebastião APM, Gularte-Mérida R, Li A, Edelweiss M, Da Cruz Paula A, Selenica P, Wen HY, Jungbluth AA, Varga Z, Palazzo J, Rubin BP, Ellis IO, Brogi E, Rakha EA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2019 Jan 18;5:6. doi: 10.1038/s41523-018-0101-7. eCollection 2019.

16.

Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors.

Arias-Stella JA 3rd, Benayed R, Oliva E, Young RH, Hoang LN, Lee CH, Jungbluth AA, Frosina D, Soslow RA, Antonescu CR, Ladanyi M, Chiang S.

Am J Surg Pathol. 2019 Mar;43(3):382-388. doi: 10.1097/PAS.0000000000001196.

PMID:
30489320
17.

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.

Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NV.

Theranostics. 2018 Oct 6;8(18):5106-5125. doi: 10.7150/thno.26585. eCollection 2018.

18.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
19.

The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.

Dogan S, Frosina D, Fayad M, de Oliveira TB, Alemar B, Rosenblum M, Tang LH, Hameed M, Xu B, Ghossein RA, Chute DJ, Weigelt B, Jungbluth AA.

Mod Pathol. 2019 Feb;32(2):205-215. doi: 10.1038/s41379-018-0126-3. Epub 2018 Sep 11.

PMID:
30206411
20.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, Da Cruz Paula A, Kumar R, Brown DN, Gularte-Mérida R, Alemar B, Bi R, Lim RS, de Bruijn I, Fujisawa S, Gardner R, Feng E, Li A, da Silva EM, Lozada JR, Blecua P, Cohen-Gould L, Jungbluth AA, Rakha EA, Ellis IO, Edelweiss MIA, Palazzo J, Norton L, Hollmann T, Edelweiss M, Rubin BP, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 Aug 30;9(1):3533. doi: 10.1038/s41467-018-05886-y.

21.

Histone H3K36M mutation and trimethylation patterns in chondroblastoma.

Lu C, Ramirez D, Hwang S, Jungbluth A, Frosina D, Ntiamoah P, Healey J, Zhu G, Chen W, Klein M, Hameed M.

Histopathology. 2019 Jan;74(2):291-299. doi: 10.1111/his.13725. Epub 2018 Nov 4.

PMID:
30098026
22.

PRAME Expression in Melanocytic Tumors.

Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ.

Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.

23.

T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders.

Pulitzer M, Geller S, Kumar E, Frosina D, Moskowitz A, Horwitz S, Myskowski P, Kheterpal M, Chan A, Dogan A, Jungbluth A.

Histopathology. 2018 Oct;73(4):653-662. doi: 10.1111/his.13671. Epub 2018 Jul 27.

24.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

25.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

26.

PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.

Hodgson A, Slodkowska E, Jungbluth A, Liu SK, Vesprini D, Enepekides D, Higgins K, Katabi N, Xu B, Downes MR.

Am J Surg Pathol. 2018 Aug;42(8):1059-1066. doi: 10.1097/PAS.0000000000001084.

27.

JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.

Xiao W, Rampal R, Zhang Y, Cimera R, Jungbluth AA, Arcila M, Roshal M, Park DC.

Leukemia. 2018 Aug;32(8):1842-1845. doi: 10.1038/s41375-018-0145-6. Epub 2018 Apr 24. No abstract available.

PMID:
29743724
28.

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen HC, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Fan D, Basili T, Da Cruz Paula A, Lozada JR, Blecua P, Muenst S, Jungbluth AA, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha EA, Chandarlapaty S, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 May 8;9(1):1816. doi: 10.1038/s41467-018-04128-5.

29.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

30.

Immunohistochemical Detection of γ/δ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues.

Jungbluth AA, Frosina D, Fayad M, Pulitzer MP, Dogan A, Busam KJ, Imai N, Gnjatic S.

Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):581-583. doi: 10.1097/PAI.0000000000000650.

PMID:
29517505
31.

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP.

Cancer Immunol Res. 2018 Feb;6(2):189-200. doi: 10.1158/2326-6066.CIR-17-0356. Epub 2018 Jan 16.

32.

ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.

Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA 3rd, Oliva E, Young RH, Hensley ML, Leitao MM Jr, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S.

Mod Pathol. 2018 Apr;31(4):674-684. doi: 10.1038/modpathol.2017.162. Epub 2017 Dec 1.

33.

Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.

Melo DH, Mamede RCM, Neder L, Silva WA Jr, Barros-Filho MC, Kowalski LP, Pinto CAL, Zago MA, Figueiredo DLA, Jungbluth AA.

Oncol Lett. 2017 Dec;14(6):6485-6496. doi: 10.3892/ol.2017.7072. Epub 2017 Sep 26.

34.

PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities.

Katabi N, Xu B, Jungbluth AA, Zhang L, Shao SY, Lane J, Ghossein R, Antonescu CR.

Histopathology. 2018 Jan;72(2):285-293. doi: 10.1111/his.13341. Epub 2017 Oct 19.

35.

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA.

Am J Surg Pathol. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911.

36.

[Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Behrendt N, Schultewolter T, Busam K, Frosina D, Spagnoli G, Jungbluth A.

Pathologe. 2017 Jul;38(4):303-311. doi: 10.1007/s00292-017-0311-z. Review. German.

PMID:
28631119
37.

BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology.

Chiang S, Lee CH, Stewart CJR, Oliva E, Hoang LN, Ali RH, Hensley ML, Arias-Stella JA 3rd, Frosina D, Jungbluth AA, Benayed R, Ladanyi M, Hameed M, Wang L, Kao YC, Antonescu CR, Soslow RA.

Mod Pathol. 2017 Sep;30(9):1251-1261. doi: 10.1038/modpathol.2017.42. Epub 2017 Jun 16.

38.

Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.

Geyer FC, Pareja F, Burke KA, Schultheis AM, Hussein YR, Ye J, De Filippo MR, Marchio C, Macedo GS, Piscuoglio S, Lim RS, Toy E, Murali R, Jungbluth AA, Reis-Filho JS, Soslow RA, Weigelt B.

Histopathology. 2017 Sep;71(3):480-487. doi: 10.1111/his.13240. Epub 2017 Jun 16.

39.

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NKV, Mora J, Sosnik A, Carcaboso AM.

J Control Release. 2017 Jun 10;255:108-119. doi: 10.1016/j.jconrel.2017.04.016. Epub 2017 Apr 12.

40.

Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors.

Busam KJ, Pulitzer MP, Coit DC, Arcila M, Leng D, Jungbluth AA, Wiesner T.

Mod Pathol. 2017 Jun;30(6):877-883. doi: 10.1038/modpathol.2017.8. Epub 2017 Mar 10.

41.

Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.

Sigel CS, Guo H, Sigel KM, Zhang M, Rekhtman N, Lin O, Klimstra DS, Jungbluth AA, Tang LK.

Cancer Cytopathol. 2017 Mar;125(3):188-196. doi: 10.1002/cncy.21817. Epub 2017 Jan 17.

42.

IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.

Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, Piscuoglio S, Ng CK, Jungbluth AA, Balss J, Pusch S, Baker GM, Cole KS, von Deimling A, Batten JM, Marotti JD, Soh HC, McCalip BL, Serrano J, Lim RS, Siziopikou KP, Lu S, Liu X, Hammour T, Brogi E, Snuderl M, Iafrate AJ, Reis-Filho JS, Schnitt SJ.

Cancer Res. 2016 Dec 15;76(24):7118-7129. Epub 2016 Oct 20.

43.

Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules.

Busam KJ, Shah KN, Gerami P, Sitzman T, Jungbluth AA, Kinsler V.

Am J Surg Pathol. 2017 Mar;41(3):396-404. doi: 10.1097/PAS.0000000000000769.

44.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.

45.

A Novel Technique for the Generation of Multitissue Blocks Using a Carrier.

Frosina D, Jungbluth AA.

Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):668-672.

46.

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.

Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P, Cheng EH, Giancotti FG, Lee W, Berger MF, Tickoo SK, Reuter VE, Hsieh JJ.

Nat Commun. 2016 Oct 7;7:13131. doi: 10.1038/ncomms13131.

47.

HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.

de Barros E Lima Bueno R, Ramão A, Pinheiro DG, Alves CP, Kannen V, Jungbluth AA, de Araújo LF, Muys BR, Fonseca AS, Plaça JR, Panepucci RA, Neder L, Saggioro FP, Mamede RC, Figueiredo DL, Silva WA Jr.

Tumour Biol. 2016 Nov;37(11):15087-15096. Epub 2016 Sep 22.

PMID:
27658780
48.

Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma.

Zhou Y, Rosenblum MK, Dogan A, Jungbluth AA, Chiu A.

J Hematop. 2015 Dec;8(4):235-241. Epub 2015 Mar 18.

49.

BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities.

Kao YC, Sung YS, Zhang L, Jungbluth AA, Huang SC, Argani P, Agaram NP, Zin A, Alaggio R, Antonescu CR.

Am J Surg Pathol. 2016 Dec;40(12):1670-1678.

50.

RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.

Lemetre C, Vieites B, Ng CK, Piscuoglio S, Schultheis AM, Marchiò C, Murali R, Lopez-García MA, Palacios JC, Jungbluth AA, Terracciano LM, Reis-Filho JS, Weigelt B.

Eur J Cancer. 2016 Sep;64:149-58. doi: 10.1016/j.ejca.2016.05.028. Epub 2016 Jul 14.

Supplemental Content

Loading ...
Support Center